Allergy medication that can be taken with CBD oil is a question many UK adults are asking as CBD supplements become increasingly popular. With a wide range of antihistamines, intranasal corticosteroids, and other allergy treatments available on the NHS and over the counter, understanding how CBD oil may interact with these medicines is essential for safe use. CBD is metabolised via the liver's cytochrome P450 enzyme system, which is shared by several allergy drugs, creating the potential for pharmacokinetic interactions. This article outlines the key considerations, lower-risk options, and when to seek professional advice.
Summary: No allergy medication is entirely risk-free when combined with CBD oil, but second-generation antihistamines such as fexofenadine and cetirizine, and intranasal corticosteroids at standard doses, are considered to carry a lower theoretical interaction risk than first-generation antihistamines or systemic allergy drugs.
- CBD is metabolised via CYP450 liver enzymes (CYP2C19, CYP3A4, CYP2C9, CYP2D6) and inhibits these enzymes, potentially raising plasma levels of allergy drugs sharing the same pathways.
- First-generation antihistamines such as chlorphenamine combined with CBD risk additive CNS depression, increasing drowsiness and impairing coordination.
- Fexofenadine and cetirizine undergo minimal hepatic metabolism, making them among the lower-risk antihistamines when used alongside CBD oil.
- The FSA advises healthy adults to take no more than 10 mg of CBD per day from food supplements, and recommends consulting a doctor before use if taking any medication.
- Only Epidyolex holds a UK marketing authorisation as a CBD-based medicine; unlicensed CBD food supplements lack equivalent clinical interaction data.
- Suspected adverse effects from combining CBD with allergy medication should be reported to the MHRA via the Yellow Card scheme.
Table of Contents
- Common Allergy Medications Available in the UK
- How CBD Oil May Interact With Antihistamines and Allergy Drugs
- Which Allergy Medications Are Considered Lower Risk With CBD Oil
- What the Evidence Says About CBD Oil and Drug Interactions
- MHRA and NHS Guidance on Using CBD Oil Alongside Medication
- When to Speak to a GP or Pharmacist Before Combining Treatments
- Frequently Asked Questions
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Common Allergy Medications Available in the UK
UK allergy medications include first- and second-generation antihistamines, intranasal corticosteroids, leukotriene receptor antagonists, and topical treatments; adrenaline auto-injectors are reserved for anaphylaxis emergencies.
Allergy medications in the UK are widely available both over the counter and on prescription, and they fall into several distinct categories. The most commonly used are antihistamines, which work by blocking histamine H1 receptors to reduce symptoms such as sneezing, itching, and a runny nose. These include:
-
First-generation antihistamines such as chlorphenamine (Piriton), which cause sedation
-
Second-generation antihistamines such as cetirizine, loratadine, and fexofenadine, which are generally non-drowsy
Other allergy medication classes include:
-
Intranasal corticosteroids such as beclometasone and fluticasone, used for allergic rhinitis
-
Leukotriene receptor antagonists such as montelukast, prescribed for allergic asthma and rhinitis
-
Topical treatments including antihistamine eye drops (e.g., sodium cromoglicate), antihistamine nasal sprays, and short-term nasal decongestants
Topical corticosteroids are commonly prescribed for atopic dermatitis (eczema) flares, whilst systemic corticosteroids may occasionally be used for severe allergic conditions under medical supervision. Adrenaline auto-injectors (available in the UK as EpiPen, Jext, and Emerade) are reserved for emergency first-line treatment of anaphylaxis; in the event of a suspected anaphylactic reaction, use the adrenaline auto-injector immediately and call 999. Antihistamines and corticosteroids are not first-line treatments for anaphylaxis and steroids are not routinely recommended in this setting, in line with Resuscitation Council UK guidance.
Understanding which category your allergy medication falls into is important when considering any additional supplement, including cannabidiol (CBD) oil. Different drug classes carry different interaction risks, and this distinction becomes particularly relevant when assessing safety alongside CBD products. Always check the patient information leaflet supplied with your medication and consult a healthcare professional if you are unsure about your specific treatment.
Still have questions? message our pharmacists for free →
| Allergy Medication | Drug Class | CBD Interaction Risk | Mechanism of Concern | Key Caution |
|---|---|---|---|---|
| Fexofenadine | Second-generation antihistamine | Low | Minimally hepatically metabolised; excreted largely unchanged. P-gp/OATP transporter effects uncertain. | Least likely antihistamine to interact via CYP450; transporter effects unclear. |
| Cetirizine | Second-generation antihistamine | Low | Minimal hepatic metabolism; primarily renally excreted. | Can cause drowsiness in some; monitor for increased sedation with CBD. |
| Loratadine | Second-generation antihistamine | Low–Moderate | Metabolised via CYP3A4 and CYP2D6; CBD inhibits both enzymes. | No significant sedation risk, but some CYP450 interaction potential exists. |
| Chlorphenamine (Piriton) | First-generation antihistamine | Moderate–High | CYP450 metabolism plus additive CNS depression with CBD. | Increased drowsiness, impaired coordination; avoid driving or operating machinery. |
| Beclometasone / Fluticasone nasal spray | Intranasal corticosteroid | Low (at standard doses) | Predominantly local action; minimal systemic absorption at recommended doses. | Potent CYP3A4 inhibition by CBD could theoretically raise systemic exposure at higher doses. |
| Montelukast | Leukotriene receptor antagonist | Moderate (theoretical) | Metabolised via CYP3A4, CYP2C8, and CYP2C9, all inhibited by CBD. | Clinical evidence in humans limited; consult GP or pharmacist before combining. |
| Systemic corticosteroids | Corticosteroid (oral/injectable) | Moderate | Hepatic metabolism via CYP3A4; CBD inhibition may raise plasma corticosteroid levels. | Use only under medical supervision; inform prescriber if taking CBD. |
How CBD Oil May Interact With Antihistamines and Allergy Drugs
CBD inhibits CYP450 enzymes including CYP3A4 and CYP2C19, potentially raising plasma concentrations of allergy drugs; combining CBD with sedating antihistamines also risks additive CNS depression.
CBD (cannabidiol) is metabolised primarily in the liver via the cytochrome P450 (CYP450) enzyme system — principally CYP2C19 and CYP3A4 — as well as via UDP-glucuronosyltransferases (UGT1A9 and UGT2B7). CBD is also an inhibitor of several CYP enzymes, including CYP2C19, CYP3A4, CYP2C9, and CYP2D6. Many allergy medications share these metabolic pathways, which creates the potential for pharmacokinetic interactions — meaning CBD may alter how quickly or slowly these drugs are broken down in the body.
When CBD inhibits CYP3A4 or CYP2C19, it can slow the metabolism of certain drugs, leading to higher plasma concentrations than intended. This could theoretically increase both the therapeutic effects and the side effects of those medications. Claims that CBD induces certain enzymes and thereby reduces drug effectiveness are not well supported by robust human clinical data and should be interpreted with caution.
For first-generation antihistamines such as chlorphenamine, there is an additional concern: both CBD and these older antihistamines have sedative properties. Combining them may produce additive central nervous system (CNS) depression, increasing drowsiness, impaired coordination, and reduced alertness — which can be hazardous, particularly when driving or operating machinery.
Not sure if this is normal? chat with one of our pharmacists →
Montelukast, a leukotriene receptor antagonist, is metabolised via CYP3A4, CYP2C8, and CYP2C9, suggesting a theoretical interaction with CBD, though clinical evidence in humans remains limited. Intranasal corticosteroids used at standard doses are largely locally acting and carry a lower systemic interaction risk, though systemic corticosteroids metabolised hepatically warrant more caution.
It is important to note that interaction potential does not automatically mean harm will occur, but it does highlight the need for professional guidance before combining treatments.
Which Allergy Medications Are Considered Lower Risk With CBD Oil
Fexofenadine and cetirizine carry a lower CYP450 interaction risk due to minimal hepatic metabolism, and intranasal corticosteroids at standard doses have limited systemic absorption, reducing interaction likelihood.
Whilst no allergy medication can be declared entirely risk-free when combined with CBD oil, some are considered to carry a lower theoretical interaction risk based on their pharmacological profiles.
Second-generation, non-sedating antihistamines are generally regarded as lower risk compared to first-generation alternatives, for the following reasons:
-
Loratadine is metabolised via CYP3A4 and CYP2D6, so some interaction potential exists, but it lacks significant sedative properties, reducing the risk of additive CNS depression
-
Fexofenadine is minimally metabolised by the liver and is largely excreted unchanged — this makes it one of the least likely antihistamines to interact with CBD at the CYP450 level. However, fexofenadine is a substrate of drug transporters (P-glycoprotein and OATP), and whether CBD meaningfully affects these transporters in clinical practice remains uncertain
-
Cetirizine undergoes minimal hepatic metabolism and is primarily renally excreted, also suggesting a lower interaction risk via the CYP450 pathway. Patients with renal impairment should follow the dose adjustments specified in the cetirizine patient information leaflet, as reduced renal clearance may affect drug levels independently of CBD
Intranasal corticosteroids such as beclometasone nasal spray, when used at recommended doses, act predominantly locally within the nasal passages with minimal systemic absorption, making significant drug interactions with CBD less likely in practice. It should be noted, however, that potent CYP3A4 inhibitors can theoretically increase systemic corticosteroid exposure; whilst this is unlikely to be clinically significant with standard nasal doses, it is a consideration at higher exposures.
It is also worth noting that even second-generation antihistamines such as cetirizine can cause drowsiness in some individuals; patients should monitor for increased sedation when combining any antihistamine with CBD.
Lower risk does not mean no risk. Individual factors such as CBD dose, frequency of use, the specific CBD product formulation, and a person's overall health status and other medications all influence the actual risk. There is currently no officially approved list of allergy medications deemed safe to combine with CBD oil, and professional advice should always be sought before making any changes to your treatment regimen.
What the Evidence Says About CBD Oil and Drug Interactions
Evidence from Epidyolex's regulatory data confirms CBD inhibits CYP enzymes, but robust clinical safety data for CBD combined with over-the-counter allergy medications specifically remains lacking.
The evidence base for CBD oil and drug interactions is growing but still limited, particularly in relation to allergy medications specifically. Much of what is currently understood comes from studies conducted in the context of CBD's licensed pharmaceutical form, Epidyolex (cannabidiol), which holds a UK marketing authorisation for certain forms of epilepsy. The European Medicines Agency (EMA) European Public Assessment Report (EPAR) and the UK Summary of Product Characteristics (SmPC) for Epidyolex document clinically significant interactions with antiepileptic drugs — most notably clobazam, whose active metabolite levels are increased via CYP2C19 inhibition by CBD — providing a framework for understanding CBD's broader interaction potential.
Laboratory (in vitro) studies consistently show that CBD inhibits several CYP450 enzymes, including CYP2C19, CYP3A4, CYP2C9, and CYP2D6, as well as UGT enzymes. However, translating in vitro findings to real-world clinical outcomes is complex, as factors such as bioavailability, dose, route of administration, and individual genetic variation in enzyme activity all play a role.
A 2020 review published in Cannabis and Cannabinoid Research highlighted that CBD has the potential to interact with a wide range of medications, though the clinical significance varies considerably. For most over-the-counter allergy medications used at standard doses, there is currently no confirmed clinical evidence of serious harm when combined with low-to-moderate doses of CBD oil — however, the absence of reported harm should not be interpreted as evidence of safety, as robust prospective safety data for these specific combinations is lacking.
Consumers using unlicensed CBD food supplements should be aware that these products are not subject to the same rigorous clinical testing as Epidyolex, meaning interaction data specific to those products is largely absent. Caution and professional consultation remain the most evidence-aligned approach.
MHRA and NHS Guidance on Using CBD Oil Alongside Medication
The NHS advises informing your GP or pharmacist before taking CBD oil with any medication; the FSA recommends a maximum of 10 mg CBD per day for healthy adults using food supplements.
In the UK, CBD oil sold as a food supplement is regulated by the Food Standards Agency (FSA) rather than the MHRA, provided it does not make medicinal claims. The Medicines and Healthcare products Regulatory Agency (MHRA) oversees CBD products that are marketed for medicinal purposes, and only Epidyolex currently holds a UK marketing authorisation as a CBD-based medicine.
The MHRA has not issued specific guidance on combining CBD food supplements with allergy medications. However, it has previously warned consumers to exercise caution when using CBD products alongside prescribed medicines, noting that interactions are possible and that the quality and concentration of CBD in unlicensed supplements can vary significantly between products and batches.
The NHS advises patients to inform their GP or pharmacist if they are taking or considering taking CBD oil, particularly if they are on regular prescription medication. The NHS also notes that CBD can cause side effects including:
-
Fatigue and drowsiness
-
Changes in appetite
-
Diarrhoea
-
Potential liver enzyme elevations at higher doses
The FSA currently advises that healthy adults consume no more than 10 mg of CBD per day from food supplements. The FSA also advises that CBD supplements are not recommended for people under 18 years of age, and should be avoided during pregnancy or breastfeeding. People taking any medication should consult a doctor before using CBD supplements.
If you experience any suspected side effects that you believe may be related to CBD oil or its interaction with your allergy medication, you can report these to the MHRA via the Yellow Card scheme (available at yellowcard.mhra.gov.uk). This helps the MHRA monitor the safety of medicines and supplements used in the UK.
Whilst there is no official NHS or MHRA protocol specifically addressing allergy medication and CBD combinations, the overarching message from UK regulatory bodies is one of informed caution and professional consultation.
When to Speak to a GP or Pharmacist Before Combining Treatments
Consult a GP or pharmacist before combining CBD with any prescription allergy medication, or if you develop new symptoms such as increased drowsiness, as spacing doses does not reliably prevent metabolic interactions.
Consulting a GP or pharmacist before combining CBD oil with any allergy medication is strongly advisable, and in certain circumstances it is essential. Healthcare professionals can review your full medication list, assess your individual risk factors, and provide personalised guidance that general information cannot replace.
You should speak to a GP or pharmacist if:
-
You are taking prescription allergy medication, including montelukast, systemic corticosteroids, or immunotherapy treatments
-
You have been prescribed any other regular medication for conditions such as epilepsy, heart disease, or mental health, as these may carry higher interaction risks
-
You experience new or worsening symptoms after starting CBD oil, such as increased drowsiness, dizziness, or changes in how well your allergy medication seems to be working
-
You are considering giving CBD oil to a child or young person under 18, as the FSA advises CBD supplements are not recommended for this age group
-
You have liver or kidney disease, which may affect how both CBD and allergy drugs are processed
-
You are pregnant or breastfeeding, as the FSA advises avoiding CBD supplements in these circumstances
A pharmacist — accessible without an appointment at most high street pharmacies — is an excellent first point of contact for questions about over-the-counter allergy medications and CBD supplements. They can check for known interactions using clinical databases and advise on your individual circumstances.
It is important to understand that spacing out doses of CBD and your allergy medication will not reliably prevent metabolic interactions. Enzyme-mediated pharmacokinetic interactions depend on the inhibitory effect of CBD on liver enzymes, which persists regardless of the timing of doses. Adjusting your regimen should only be done on the advice of a healthcare professional.
If you are already combining CBD oil with allergy medication and have concerns, do not stop either treatment abruptly without professional advice. Instead, book a medication review with your GP, who can assess whether any adjustments are needed. If you suspect a serious adverse reaction, report it via the MHRA Yellow Card scheme. Open, honest communication with your healthcare team is the safest approach when managing allergy symptoms alongside any supplement use.
Frequently Asked Questions
Which antihistamine is least likely to interact with CBD oil?
Fexofenadine is considered one of the least likely antihistamines to interact with CBD oil at the CYP450 level, as it undergoes minimal hepatic metabolism and is largely excreted unchanged. Cetirizine is also considered lower risk for the same reason, though individual factors and CBD dose still influence overall safety.
Can I take CBD oil with loratadine or cetirizine?
Loratadine and cetirizine are second-generation antihistamines with a lower theoretical interaction risk with CBD oil compared to first-generation alternatives, but neither combination is officially approved as safe. You should consult a pharmacist or GP before combining them, particularly if you take other regular medications.
Does the NHS or MHRA recommend any allergy medication as safe to use with CBD oil?
Neither the NHS nor the MHRA has issued an approved list of allergy medications deemed safe to combine with CBD oil. UK regulatory guidance recommends informing your GP or pharmacist before using CBD supplements alongside any medication, and the FSA advises a maximum of 10 mg of CBD per day for healthy adults.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
